Transaction Description
Gemstone Capital acted as financial advisor and joint bookrunner in this transaction. The Rights Issue was compromised of a maximum of 215,187,249 units, consisting of shares and warrants. Provided that the Rights Issue was fully subscribed, the Company would receive initial proceeds of approximately SEK 49.5 million before the deduction of issue costs. The Rights Issue was covered by guarantee commitments of SEK 30.1 million. The issue was subscribed to a total of 60.9 percent. Through the Rights Issue, the Company thus received gross proceeds of approximately SEK 30.2 million.
Contact Person
Company Description
Qlife has developed and patented the Egoo Health test platform, which integrates several technologies that potentially can test for a wide range of biomarkers and viruses – protein-based and molecular. The technology is intended to be easy to use, cost-effective, and suitable for use in people’s homes or decentralized testing sites. Qlife is focused on the Hospital-at-Home market, a B2B market that represents a global trend where healthcare facilities worldwide actively explore opportunities to provide medical care to patients at home instead of in hospitals. The primary challenge in enabling home patient care lies in accessing high-quality clinical blood data without the need for hospitalization or visits by medical personnel. Not all patients can be cared for at home, but a significant proportion of stable patients can benefit from this approach. A prerequisite is the consistent collection of important clinical biomarker data that can be continuously monitored by healthcare professionals.
